Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
FactSet has been swept up in a broader 'AI-phobia' rotation that punished legacy data and software names. The business still generates strong cash flow ($647M FCF), sports a healthy ROE (27.7%) and carries a modest leverage profile (debt/equity 0.63). At roughly $7.38B market cap and a P/E near 12-12.6, the stock offers a favorable risk/reward for …
Ezcorp (EZPW) combines steady pawn-loan economics, a string of accretive acquisitions, and healthy free cash flow into a valuation that still looks reasonable. After closing a major roll-up that adds 105 stores and $147M of revenue, the company offers a mid-to-long-term trade with clear entry, target and stop rules to capture upside while limiting …
T‑Mobile reported better-than-expected Q4 results and gave 2026 free cash flow guidance of $18.0-18.7 billion. The name pulled back to near $215 after a volatile start to the year; technicals and short-interest dynamics favor a rebound. This trade idea lays out an actionable entry at the current level, a stop under the 50-day moving average, and a …
The market has confused cyclical hardware noise with a durable margin collapse. Dell's mix of installed enterprise customers, meaningful free cash flow ($4.45B), and a sub-1x EV/sales valuation create a clear asymmetric trade. Entry at $118.50, stop $98.00, target $178.00 - long term (180 trading days).
Elliott Investment Management's disclosed 10%+ stake and activist campaign is a high-probability catalyst for Norwegian Cruise Line (NCLH). The firm trades at an attractive EV/EBITDA and P/E relative to potential upside if SG&A and capital allocation are tightened. This trade targets a re-rating to the $28 area over a mid-term horizon while keeping…
Catalyst Pharmaceuticals is a commercial-stage rare-disease specialty drug company with clear levers to grow revenue from its FDA-approved portfolio. Recent regulatory wins and a patent settlement that delays broad generic entry create a multi-quarter runway. Valuation is reasonable relative to cash generation; this trade targets upside to $32 with…
Meta’s core advertising business remains cash-generative while AI and new hardware initiatives are reaccelerating growth. Market sentiment is tepid, technicals show short-term fatigue, and headline sellers have pressured the stock below its recent trading averages. That combination creates an asymmetric trade: overweight risk-reward with a clear st…
Bristol-Myers Squibb's oncology franchise and data-rich 2026 give the company a near-term bull case. The stock trades at roughly $59.71 with a market cap near $122B, supported by a high-margin growth portfolio, solid free cash flow and a 4%+ dividend. We outline a mid-term long trade (45 trading days) to capture upside around clinical and commercia…
eBay is showing renewed top-line momentum after a strong Q4, a strategic Depop acquisition and a fresh $2B buyback authorization. The shares trade at a mid-teens P/E relative to recent earnings, with free cash flow and a modest dividend supporting returns. We lay out an actionable mid-term swing trade with clear entry, stop and target and the risks…
Adobe (ADBE) has been hammered alongside the broader software sell-off, trading just above its 52-week low with RSI near 29. Fundamentals are intact: roughly $9.9B in free cash flow, a market cap near $106B and a P/E around 15. That mix of earnings power, low leverage and compressed multiples creates a tactical long trade: enter $259.00, stop $246.…
Robinhood (HOOD) has transformed its revenue mix and risk profile enough to merit a rating upgrade. With retail participation stabilizing, recurring subscription and cash management income growing, and the broader market structure supportive, now is a reasonable entry for a defined-risk long. This trade idea lays out an entry at $32.00, a protectiv…
Carvana's stock has been knocked back by a high-profile short-seller report and ensuing legal inquiries, but the company still shows sizable revenue, positive free cash flow and improving operating margins. This trade idea lays out a directional long with a clear entry, stop and target sized for a mid-term swing (45 trading days) while acknowledgin…
Equinox Gold just removed a heavy debt overhang, set 2026 production guidance at 700k-800k ounces, and kicked off capital return programs. With enterprise value low relative to near-term production and bullish technicals, this is a mid-term long trade sized for conviction but capped with a pragmatic stop.
NRG (NRG) combines newly acquired flexible generation, a virtual power plant capability, and stronger FY26 guidance to offer an actionable long trade into the AI-driven electricity demand cycle. Valuation is reasonable on an EV/EBITDA of ~12 and FCF guidance that now targets $2.8-$3.3 billion for FY26; technicals show bullish momentum. This trade t…
Ouster (OUST) makes high-resolution digital lidar sensors for machines, vehicles and infrastructure. At $18.25 the stock prices in heavy growth and some execution risk. We prefer a long position sized for high volatility: entry $18.25, stop $14.00, target $28.00 over a long-term (180 trading days) horizon. Key upside is accelerated Physical AI adop…
Canadian Natural offers a 4%+ yield backed by strong operating cash flow, conservative capital discipline and heavy-crude optionality. Valuation is reasonable for a large integrated oil producer (market cap ~$88.2B, P/E ~18.4), and near-term technical strength creates a tactical entry window. This trade idea lays out an actionable long-term plan wi…
Novo Nordisk (NVO) is trading near $48.47 after a steep re-rating driven by competitive share loss, welcome price pressure, and conservative 2026 guidance. At a market cap of $213.8B and a PE of 14.1, the stock looks materially cheaper than its 52-week peak. This trade idea advocates a tactical long: entry at $48.47, stop at $43.08, target $60.00 o…
Alphabet's scale in cloud, search, and multimodal AI gives it a clearer path to near-term monetization than Apple's device-first approach. Valuation, cash flow and technicals create an actionable long trade: enter near $300, stop at $281, target $350 over the next 45 trading days while watching cloud customer growth and Gemini monetization as catal…
Gencor (GENC) sits on a $57.4 million backlog and $147.7 million in cash and securities with no debt. That mix - an orderbook large relative to trailing annual sales and a net-cash balance sheet - supports a long trade into fiscal 2026 as order conversion resumes. Entry $15.14, stop $13.50, target $20.00, long-term (180 trading days).
Nu Skin (NUS) trades at depressed multiples despite positive free cash flow, a modest debt load, and returns on capital consistent with a healthy business. This trade idea lays out a long trade with defined entry, stop, and target using current valuation and technical context - the idea is to own the stock while management executes on customer acqu…
Electrolux's recent margin improvement, reinforced by SEK 4.0bn in cost efficiency gains and Q4 operating margin expansion to 4.3%, suggests earnings upside that the market has not fully priced. With a $2.51B market cap, benign technicals and an improving product footprint in North America, ELUXY looks like a mid-term long trade. Entry $17.90, stop…
Viavi has moved beyond a pure telecom-capex rebound. Q2 strength, upbeat guidance and expanding addressable markets in AI, data-center testing and defense/aerospace make the stock a tactical long. The trade uses a precise entry at $26.32, a stop at $22.00 and a $37.00 target over a 180 trading-day horizon.
Vanda (VNDA) is a small-cap pharma with a pending regulatory event this week that could re-rate the stock. At roughly $6, market-implied valuation is modest (EV/Sales ~1.3) but fundamentals and technicals are weak. This is a high-risk, event-driven trade: defined-entry long before PDUFA with a tight stop and an upside target near prior highs.
Ares Capital (ARCC) looks vulnerable. High exposure to software & services, signs of lingering credit deterioration, and an environment of falling rates that erodes BDC yield economics create a trifecta that can pressure the stock and the dividend. Valuation (P/B ~0.97, P/E ~10.7, market cap ~$13.9B) discounts some risk, but not all. Trade idea: sh…
NerdWallet (NRDS) looks undervalued relative to its cash generation and growth profile. At about $10 a share, P/E near 10 and EV/sales below 1, the stock offers an asymmetric reward-to-risk for a mid-term swing. This trade idea outlines an entry, stop, and target with clear catalysts and risks to watch.
